International Journal of Drug Delivery Technology
Volume 14, Issue 2

Biosynthesis of Platinum Nanoparticles PlNPs by Bacterial Strain Rhodococcus erythropolis

Prabir Kumar Pal*, Naveen Kumar Choudhary

Faculty of Pharmacy, B. R. Nahata College of Pharmacy, Mandsaur University, Mansaur, Madhya Pradesh, India.

Received: 03rd February, 2024; Revised: 19th April, 2024; Accepted: 10th June, 2024; Available Online: 25th June, 2024 

ABSTRACT

The biosynthesis of platinum nanoparticles (PlNPs) using the bacterial strain Rhodococcus erythropolis offers a greener alternative to conventional chemical and physical synthesis methods. This study explores the potential of R. erythropolis to produce PlNPs by leveraging its biological machinery to reduce platinum ions and stabilize the resulting nanoparticles. The biosynthesis was conducted under varying conditions of pH, temperature, and sodium platinite concentrations to optimize yield and particle characteristics. The nanoparticles were characterized. The outcome reflects that PlNPs exhibit distinct size-dependent optical properties and crystallinity, with extracellular proteins from R. erythropolis playing a crucial role in nanoparticle stabilization. The optimized biosynthesis process produced PlNPs with high colloidal stability and significant potential for applications in catalysis and environmental remediation. This study advances the understanding of microbial nanoparticle production, highlighting a sustainable pathway for the synthesis of biocompatible and catalytically active platinum nanoparticles.

Keywords: Platinum nanoparticles, Rhodococcus erythropolis, Biosynthesis, Nanoparticle characterization, Green synthesis. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.2.50

How to cite this article: Pal PK, Choudhary NK. Biosynthesis of Platinum Nanoparticles PlNPs by Bacterial Strain Rhodococcus erythropolis. International Journal of Drug Delivery Technology. 2024;14(2):938-944

REFERENCES

  1. Bach The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002;307:911-920.
  2. Bajpai SK, Bajpai M R. Dengree; Chemically treated gelatin capsules for colon-targeted drug delivery: A novel approach. J Appl Polym Sci. 2003;89:2277-2282.
  3. Basit Oral colon-specific drug delivery using amylose-based film coatings. Pharm Tech Eur. 2000;12(2):30-36.
  4. Challa T, Vynala V, Allam KV. Colon specific drug delivery system: A review on primary and novel approaches. Int J Pharmaceutical Sciences Review and 2011;7(2):171-181.
  5. Chandran S, Sanjay KS, Asghar A. Microspheres with pH modulated release: design and characterization of formulation variables for colonic J Microencapsul. 2009;26:420-431.
  6. Dhar Environmental factors associated with Crohn’s disease in India-there’s more to it than meets the eye. Indian J Gastroenterol. 2011;30(6):255-256.
  7. Dube V, Payghan SA, Souza JI. Development of colon targeted lornoxicam matrix tablet. Int J Pharm Res Development. 2011;3(6):226-32.
  8. El-Kamel AH, Abdel-Aziz AM, Fatani AJ, El-Subbagh Oral colon targeted delivery systems for treatment of inflammatory bowel diseases: Synthesis, in vitro and in vivo assessment. Int J Pharm. 2008; 358:248-255.
  9. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hard castle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects.Gut.1988; 29:1035-1041.
  10. Fukui EN, Miyamura KV and Kobayashi M. Preparation of enteric coated time released press coated tablets and evaluation of their function by in vivo and in vitro tests for colon Int J Pharm. 2000; 204:7-15.
  11. Gandhy US, Kim HK, Larsen L, Rosengren R and Safe S. Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein transcription factors by targeting microRNAs; BMC cancer. 2012; 12:564.
  12. Huttunen KM and Rautio J; An efficient way to breach delivery and targeting barriers; Current Topic in Medicinal Chemistry. 2011;11:2265-2287.
  13. Javid GSA, Zargar SR, Khan AR, Khan BA,et all. Incidence of colorectal cancer in Kashmir valley, India; Indian J 2011;30(1):7-11.
  14. Jobin C, Bradham CA and Russo Curcumin blocks cytokine- mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol. 1999; 163:3474-3483.
  15. Kulkarni Pharmacology of GIT; In: Handbook of experimental pharmacology. Vallabh prakashan, New Delhi. 1999; 148-150.
  16. Kumar SND, Vijaybhaskar PKR and Pratima S. Pathological observations on the treatment of oral sub mucous fibrosis of curcumin gels in animal models. Der Pharmacia Letter. 2012;4(3):919-926.
  17. Lamprecht A H, Yamamoto H, Takeuchi Y, Design of pH-sensitive microspheres for the colonic delivery of the immunosuppressive drug tacrolimus. Eur J Pharm Biopharm. 2004; 58:37-43.
  18. Muaola MJ, Shinoleava and Taleada K. Evaluation of intestinal pressure controlled colon delivery capsule containing caffeine as a model drug in human volunteer. J control release. 1998; 52:119-129.
  19. Mura CA, Nacher V, Merino MM, Sanjuan MM, Loy G, Fadda AM, Diez-Sales O. Design, characterization and in vitro evaluation of 5-aminosalicylic acid loaded N-succinyl chitosan microparticles for colon-specific Colloids and Surface B: Biointerfaces. 2012; 94:199-205.
  20. Abdulazeem L and Abd FG. Biosynthesis and Characterization of Gold Nanoparticles by Using Local Serratia spp. Isolate. International Journal of Pharmaceutical Quality Assurance. 2019;10(3): 8-11.
  21. Chauhan R, Singh B, Singh MP, Malik A. Pharmacokinetic Study of Aloin Nanoparticulate: Enhanced Oral Formulation Bioavailability. International Journal of Pharmaceutical Quality Assurance. 2024;15(1):94-100.